Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 150.81
ZLTQ's Cash to Debt is ranked higher than
69% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZLTQ: 150.81 )
Ranked among companies with meaningful Cash to Debt only.
ZLTQ' s 10-Year Cash to Debt Range
Min: 6.45  Med: 9999.00 Max: No Debt
Current: 150.81
Equity to Asset 0.63
ZLTQ's Equity to Asset is ranked lower than
53% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ZLTQ: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
ZLTQ' s 10-Year Equity to Asset Range
Min: -5.35  Med: 0.71 Max: 0.89
Current: 0.63
-5.35
0.89
F-Score: 6
Z-Score: 18.05
M-Score: -2.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 3.07
ZLTQ's Operating margin (%) is ranked higher than
50% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ZLTQ: 3.07 )
Ranked among companies with meaningful Operating margin (%) only.
ZLTQ' s 10-Year Operating margin (%) Range
Min: -1082.23  Med: -28.38 Max: 1.22
Current: 3.07
-1082.23
1.22
Net-margin (%) 2.42
ZLTQ's Net-margin (%) is ranked higher than
51% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ZLTQ: 2.42 )
Ranked among companies with meaningful Net-margin (%) only.
ZLTQ' s 10-Year Net-margin (%) Range
Min: -1111.78  Med: -28.43 Max: 0.88
Current: 2.42
-1111.78
0.88
ROE (%) 7.50
ZLTQ's ROE (%) is ranked higher than
60% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ZLTQ: 7.50 )
Ranked among companies with meaningful ROE (%) only.
ZLTQ' s 10-Year ROE (%) Range
Min: -299.73  Med: -32.35 Max: 2.3
Current: 7.5
-299.73
2.3
ROA (%) 5.06
ZLTQ's ROA (%) is ranked higher than
66% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. ZLTQ: 5.06 )
Ranked among companies with meaningful ROA (%) only.
ZLTQ' s 10-Year ROA (%) Range
Min: -103.26  Med: -21.65 Max: 1.6
Current: 5.06
-103.26
1.6
ROC (Joel Greenblatt) (%) 43.34
ZLTQ's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. ZLTQ: 43.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZLTQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1849.11  Med: -546.32 Max: 28.88
Current: 43.34
-1849.11
28.88
Revenue Growth (3Y)(%) -22.30
ZLTQ's Revenue Growth (3Y)(%) is ranked lower than
88% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ZLTQ: -22.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZLTQ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -68.6  Med: -33.60 Max: -22.3
Current: -22.3
-68.6
-22.3
» ZLTQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ZLTQ Guru Trades in Q3 2014

Paul Tudor Jones 11,126 sh (New)
Steven Cohen 635,700 sh (+10.06%)
RS Investment Management 1,170,166 sh (-13.20%)
» More
Q4 2014

ZLTQ Guru Trades in Q4 2014

Steven Cohen 1,299,930 sh (+104.49%)
Paul Tudor Jones 12,767 sh (+14.75%)
RS Investment Management 736,886 sh (-37.03%)
» More
Q1 2015

ZLTQ Guru Trades in Q1 2015

Steven Cohen 1,964,508 sh (+209.03%)
Steven Cohen 1,150,721 sh (-11.48%)
Paul Tudor Jones 8,793 sh (-31.13%)
RS Investment Management 484,116 sh (-34.30%)
» More
Q2 2015

ZLTQ Guru Trades in Q2 2015

Joel Greenblatt 15,199 sh (New)
Jim Simons 115,600 sh (New)
RS Investment Management 704,066 sh (+45.43%)
RS Investment Management 704,066 sh (+45.43%)
Steven Cohen 1,407,000 sh (+22.27%)
Paul Tudor Jones 8,800 sh (+0.08%)
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 267.40
ZLTQ's P/E(ttm) is ranked lower than
97% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. ZLTQ: 267.40 )
Ranked among companies with meaningful P/E(ttm) only.
ZLTQ' s 10-Year P/E(ttm) Range
Min: 169.51  Med: 259.18 Max: 1567.27
Current: 267.4
169.51
1567.27
Forward P/E 119.05
ZLTQ's Forward P/E is ranked lower than
92% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. ZLTQ: 119.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 271.80
ZLTQ's PE(NRI) is ranked lower than
97% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. ZLTQ: 271.80 )
Ranked among companies with meaningful PE(NRI) only.
ZLTQ' s 10-Year PE(NRI) Range
Min: 171.63  Med: 263.50 Max: 1724
Current: 271.8
171.63
1724
P/B 16.99
ZLTQ's P/B is ranked lower than
99% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. ZLTQ: 16.99 )
Ranked among companies with meaningful P/B only.
ZLTQ' s 10-Year P/B Range
Min: 1.79  Med: 5.41 Max: 19.19
Current: 16.99
1.79
19.19
P/S 6.24
ZLTQ's P/S is ranked lower than
74% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ZLTQ: 6.24 )
Ranked among companies with meaningful P/S only.
ZLTQ' s 10-Year P/S Range
Min: 0.17  Med: 3.61 Max: 7.96
Current: 6.24
0.17
7.96
PFCF 95.94
ZLTQ's PFCF is ranked lower than
83% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 33.52 vs. ZLTQ: 95.94 )
Ranked among companies with meaningful PFCF only.
ZLTQ' s 10-Year PFCF Range
Min: 81.09  Med: 128.59 Max: 190.83
Current: 95.94
81.09
190.83
POCF 81.55
ZLTQ's POCF is ranked lower than
88% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 22.08 vs. ZLTQ: 81.55 )
Ranked among companies with meaningful POCF only.
ZLTQ' s 10-Year POCF Range
Min: 68.93  Med: 104.16 Max: 149.35
Current: 81.55
68.93
149.35
EV-to-EBIT 186.20
ZLTQ's EV-to-EBIT is ranked lower than
97% of the 159 Companies
in the Global Medical Devices industry.

( Industry Median: 21.34 vs. ZLTQ: 186.20 )
Ranked among companies with meaningful EV-to-EBIT only.
ZLTQ' s 10-Year EV-to-EBIT Range
Min: -231.8  Med: -6.65 Max: 655
Current: 186.2
-231.8
655
Current Ratio 2.39
ZLTQ's Current Ratio is ranked lower than
51% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ZLTQ: 2.39 )
Ranked among companies with meaningful Current Ratio only.
ZLTQ' s 10-Year Current Ratio Range
Min: 1.09  Med: 2.87 Max: 8.23
Current: 2.39
1.09
8.23
Quick Ratio 1.97
ZLTQ's Quick Ratio is ranked higher than
51% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ZLTQ: 1.97 )
Ranked among companies with meaningful Quick Ratio only.
ZLTQ' s 10-Year Quick Ratio Range
Min: 0.78  Med: 2.35 Max: 7.85
Current: 1.97
0.78
7.85
Days Inventory 107.27
ZLTQ's Days Inventory is ranked higher than
61% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. ZLTQ: 107.27 )
Ranked among companies with meaningful Days Inventory only.
ZLTQ' s 10-Year Days Inventory Range
Min: 46.43  Med: 87.28 Max: 109.81
Current: 107.27
46.43
109.81
Days Sales Outstanding 52.75
ZLTQ's Days Sales Outstanding is ranked higher than
76% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. ZLTQ: 52.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZLTQ' s 10-Year Days Sales Outstanding Range
Min: 8.79  Med: 33.80 Max: 237.12
Current: 52.75
8.79
237.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 296.55
ZLTQ's Price/Net Cash is ranked lower than
98% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 13.32 vs. ZLTQ: 296.55 )
Ranked among companies with meaningful Price/Net Cash only.
ZLTQ' s 10-Year Price/Net Cash Range
Min: 3.49  Med: 14.32 Max: 267.91
Current: 296.55
3.49
267.91
Price/Net Current Asset Value 21.19
ZLTQ's Price/Net Current Asset Value is ranked lower than
85% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. ZLTQ: 21.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZLTQ' s 10-Year Price/Net Current Asset Value Range
Min: 2.79  Med: 7.84 Max: 21.26
Current: 21.19
2.79
21.26
Price/Tangible Book 18.33
ZLTQ's Price/Tangible Book is ranked lower than
93% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. ZLTQ: 18.33 )
Ranked among companies with meaningful Price/Tangible Book only.
ZLTQ' s 10-Year Price/Tangible Book Range
Min: 2.32  Med: 5.75 Max: 18.68
Current: 18.33
2.32
18.68
Price/Median PS Value 1.75
ZLTQ's Price/Median PS Value is ranked lower than
84% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ZLTQ: 1.75 )
Ranked among companies with meaningful Price/Median PS Value only.
ZLTQ' s 10-Year Price/Median PS Value Range
Min: 0.06  Med: 0.97 Max: 1.81
Current: 1.75
0.06
1.81
Price/Graham Number 14.18
ZLTQ's Price/Graham Number is ranked lower than
97% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. ZLTQ: 14.18 )
Ranked among companies with meaningful Price/Graham Number only.
ZLTQ' s 10-Year Price/Graham Number Range
Min: 12.09  Med: 12.81 Max: 22.69
Current: 14.18
12.09
22.69
Earnings Yield (Greenblatt) (%) 0.50
ZLTQ's Earnings Yield (Greenblatt) (%) is ranked higher than
50% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ZLTQ: 0.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZLTQ' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 0.50 Max: 0.8
Current: 0.5
0.2
0.8

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 247 294 353
EPS($) 0.03 0.28 0.55
EPS without NRI($) 0.03 0.28 0.55

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
ZELTIQ Aesthetics Inc was incorporated in the state of Delaware on March 22, 2005. In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company generates revenue from sales of CoolSculpting system and from sales of consumables to its customers. Its geographical region includes North America and International. The Company's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. The Company manufactures and distributes its CoolSculpting system, including procedure packs, at its Dublin facility. The Livermore facility is used primarily for raw material storage. Through 2012 and the beginning of 2013, the Company has utilized OnCore Manufacturing LLC to manufacture and supply CoolSculpting system. ZELTIQ, CoolSculpting, and Company's logo are registered trademarks in the United States and in certain foreign countries. The design, development, manufacture, testing and sale of products are subject to regulation by governmental authorities, mainly FDA, and corresponding state and foreign regulatory agencies.
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
ZELTIQ Announces Save the Date for 2015 Investor Day Aug 17 2015 
ZELTIQ to Present at the Canaccord Genuity 35th Annual Growth Conference Aug 11 2015 
ZELTIQ Announces Conference Call and Webcast of Second Quarter 2015 Financial Results to Be Held on Jul 16 2015 
ZELTIQ to Participate at Investor Conferences in June 2015 May 20 2015 
Steven Cohen's Newest Buys, Additions and Reductions Mar 04 2015 
CoolSculpting(R) Procedure Named "Best Fat-Reducing Treatment" by NewBeauty(R) Magazine Jan 27 2015 
Steven Cohen Buys New Drug Stock, Triples Investment in Medical Company Jan 25 2015 
New Year, New You, New Findings -- New Survey Reveals What Women Expect to Gain by Keeping New Year' Jan 21 2015 
ZELTIQ to Present at J.P. Morgan 33rd Annual Healthcare Conference Jan 13 2015 
ZELTIQ to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan 05 2015 

More From Other Websites
ZELTIQ Announces Save the Date for 2015 Investor Day Aug 17 2015
ZELTIQ Announces Save the Date for 2015 Investor Day Aug 17 2015
ZELTIQ to Present at the Canaccord Genuity 35th Annual Growth Conference Aug 11 2015
ZELTIQ AESTHETICS INC Financials Aug 07 2015
Zeltiq Hits New High After Raising Guidance Again Jul 31 2015
Edited Transcript of ZLTQ earnings conference call or presentation 30-Jul-15 8:30pm GMT Jul 31 2015
Zeltiq tops Street 2Q forecasts Jul 30 2015
Zeltiq tops Street 2Q forecasts Jul 30 2015
ZELTIQ Announces Second Quarter 2015 Financial Results Jul 30 2015
ZELTIQ Aesthetics Inc Earnings Call scheduled for 4:30 pm ET today Jul 30 2015
ZELTIQ AESTHETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Jul 30 2015
ZELTIQ Announces Second Quarter 2015 Financial Results Jul 30 2015
Surging Earnings Estimates Signal Good News for ZELTIQ Aesthetics (ZLTQ) - Tale of the Tape Jul 30 2015
Why ZELTIQ Aesthetics (ZLTQ) Could Beat Earnings Estimates Again - Tale of the Tape Jul 24 2015
Piper Jaffray Starts Zeltiq At Overweight, Sees Upside Of $35/Share Jul 20 2015
Coverage initiated on ZELTIQ Aesthetics by Piper Jaffray Jul 20 2015
ZELTIQ Announces Conference Call and Webcast of Second Quarter 2015 Financial Results to Be Held on... Jul 16 2015
ZELTIQ Announces Conference Call and Webcast of Second Quarter 2015 Financial Results to Be Held on... Jul 16 2015
The Zacks Analyst Blog Highlights: Zoe's Kitchen, Schnitzer Steel Industries, Xplore Technologies... Jul 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK